Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in Unexplained Recurrent Miscarriage
NCT04228263Completed
- Sponsor
- Assiut University
- Start
- Jan 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of hydroxychloroquine in recurrent miscarriage (RPL) (2 arms), sponsored by Assiut University. Primary endpoint: Number of viable fetuses at 20 weeks gestation. Started Jan 2020; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on NCT04228263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04228263.